Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China · Delayed Price · Currency is CNY 6.44
+0.59 (10.09%)
Aug 20, 2026, 3:04 PM CST
Beijing SL Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,616 | 7,572 | 7,674 | 10,469 | 8,445 | 11,106 | |
Market Cap Growth | -21.65% | -1.34% | -26.69% | 23.97% | -23.96% | 7.03% |
Enterprise Value | 5,466 | 6,626 | 6,762 | 9,607 | 7,404 | 10,195 |
Last Close Price | 6.44 | 7.36 | 7.44 | 9.94 | 7.94 | 10.33 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 25.12 | 36.03 | 26.07 |
Forward PE | - | 19.74 | 19.74 | 30.88 | 12.35 | 12.35 |
PS Ratio | 11.18 | 12.14 | 11.62 | 10.28 | 8.04 | 9.14 |
PB Ratio | 1.30 | 1.46 | 1.38 | 1.80 | 1.54 | 2.09 |
P/TBV Ratio | 1.48 | 1.67 | 1.57 | 2.05 | 1.71 | 2.30 |
P/FCF Ratio | 21.71 | 117.04 | - | 43.29 | 37.31 | 48.77 |
P/OCF Ratio | 17.77 | 29.39 | 34.03 | 22.75 | 21.66 | 23.90 |
PEG Ratio | - | 0.49 | 0.49 | 0.74 | 0.82 | 0.82 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.24 | 10.62 | 10.24 | 9.43 | 7.05 | 8.39 |
EV/EBITDA Ratio | 29.83 | 41.65 | 37.44 | 26.28 | 28.79 | 32.68 |
EV/EBIT Ratio | - | - | 244.58 | 43.65 | 51.54 | 48.02 |
EV/FCF Ratio | 17.93 | 102.42 | - | 39.72 | 32.71 | 44.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / EBITDA Ratio | - | - | - | - | - | 0.01 |
Debt / FCF Ratio | - | - | - | - | - | 0.01 |
Net Debt / Equity Ratio | -0.23 | -0.22 | -0.35 | -0.37 | -0.26 | -0.31 |
Net Debt / EBITDA Ratio | -6.31 | -7.17 | -10.98 | -5.84 | -5.65 | -5.24 |
Net Debt / FCF Ratio | -3.79 | -17.64 | 16.26 | -8.82 | -6.42 | -7.17 |
Asset Turnover | 0.10 | 0.10 | 0.11 | 0.17 | 0.18 | 0.22 |
Inventory Turnover | 0.46 | 0.51 | 1.09 | 1.34 | 1.20 | 1.55 |
Quick Ratio | 2.07 | 1.70 | 7.27 | 6.35 | 6.02 | 6.20 |
Current Ratio | 3.39 | 2.87 | 8.60 | 7.07 | 6.92 | 7.07 |
Return on Equity (ROE) | -8.97% | -6.47% | -1.32% | 7.35% | 4.23% | 8.17% |
Return on Assets (ROA) | 0.14% | -0.08% | 0.28% | 2.26% | 1.54% | 2.38% |
Return on Invested Capital (ROIC) | 0.33% | -0.20% | 0.76% | 5.10% | 3.28% | 5.40% |
Return on Capital Employed (ROCE) | 0.20% | -0.10% | 0.50% | 3.70% | 2.60% | 3.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -7.24% | -4.59% | -0.97% | 3.98% | 2.78% | 3.84% |
FCF Yield | 4.61% | 0.85% | -1.59% | 2.31% | 2.68% | 2.05% |
Dividend Yield | 0.17% | 0.14% | 0.27% | 1.51% | 1.26% | 0.97% |
Payout Ratio | - | - | - | 24.65% | 43.83% | 24.17% |
Buyback Yield / Dilution | 8.40% | 3.49% | -4.11% | 0.28% | 1.90% | -2.55% |
Total Shareholder Return | 8.56% | 3.62% | -3.84% | 1.79% | 3.16% | -1.58% |